Anavex Life Sciences Corp., has announced it would be trading its common stock on the NASDAQ, an American/Canadian stock exchange, one of the world’s largest.
A clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer on Monday announced receiving approval to begin trading its common stock on the NASDAQ Capital Market.
The company said that its common stock will begin to trade on NASDAQ under the symbol “AVXL” at the opening of market hours on October 28, 2015.
“This is a significant milestone for Anavex. As we become a NASDAQ-listed company, our team is now able to communicate our progress with a broader audience, raise the visibility of Anavex’s capabilities, as well as generate more value for our shareholders,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex in annoucement issued on Monday.
“The NASDAQ uplisting also comes at an important time in our growth as full PART A and preliminary PART B Phase 2a clinical trial data will be presented at the CTAD conference on November 7, 2015.”
Before trading on NASDAQ commences on October 28, 2015, Anavex’s common stock will continue to trade on the OTCQX under the symbol “AVXLD.”